Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is poised for success in the rare disease market with its pipeline candidate sparsentan, which is in late-stage development for rare kidney disorders such as FSGS and IgAN. The company has reported strong patient start forms (PSFs) growth for sparsentan, with an average 40% year-over-year increase over the last four quarters, and has also observed a positive market response for its recently approved treatment for FSGS. Travere has established a solid commercial infrastructure and is well-positioned for future growth and execution in this underserved market, making it an attractive investment opportunity for investors.

Bears say

Travere Therapeutics is facing numerous challenges as a company, including a recent missed revenue target for their Filspari drug. Despite potential inflection points in their pipeline, the overall trajectory of patient start forms and PSF numbers are not strong enough to support substantial long-term growth for the company. Additionally, the recent approval of their drug Filspari for FSGS has not resulted in a significant increase in revenue or addressable population, raising concerns about the company's overall growth potential.

Travere Therapeutics (TVTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 11 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.